Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-05-10

FDA Approved: REXULTI — Supplemental Application (Otsuka America Pharmaceutical, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Rexulti (brexpiprazole) submitted by Otsuka America Pharmaceutical, Inc., resulting in changes to the drug's lab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • REXULTI (brexpiprazole)

Snippet

SUPPL AP for REXULTI (BREXPIPRAZOLE)